Pancreatic Cancer Research

ResearcherNational Institutes of HealthActive in the last 2 years

Francisco X. Real

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9501-498X; OpenAlex author ID A5060086359. Sources: OpenAlex.

Their work

Papers
58 (first author 3, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
202
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 1 paper · 2014: 4 papers · 2015: 4 papers · 2016: 3 papers · 2017: 4 papers · 2018: 3 papers · 2019: 3 papers · 2020: 4 papers · 2021: 8 papers · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers · 2025: 5 papers · 2026: 6 papers

Papers 50 of 58

  1. Multimodal profiling of pancreatic cancer reveals a TIMP-1-dominated secretory profile determining pro-tumor immunoinstruction in human cancers. Co-author DOI 10.1016/j.xcrm.2025.102546↗
  2. Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
  3. Pancreatic cancer. Co-author DOI 10.1038/s41572-026-00699-6↗
  4. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  5. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  6. GATA4 loss promotes mutant Kras -driven pancreatic ductal adenocarcinoma in the absence of canonical precursor lesions Last author DOI 10.64898/2026.05.22.724502↗
  7. Low type-2 immune effectors modulate atopic diseases' protective role in pancreatic cancer risk. Co-author DOI 10.1002/ijc.35397↗
  8. Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33. Co-author DOI 10.1038/s41467-025-59109-2↗
  9. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  10. A Common CTRB misfolding variant associated with pancreatic cancer risk causes ER stress and inflammation in mice. Last author DOI 10.1136/gutjnl-2024-333406↗
  11. Development of a consensus molecular classifier for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13073-025-01568-9↗
  12. PDAC heterogeneity resolved spatially at the single-cell level: new biological answers, new questions on optimal translation†. First author DOI 10.1002/path.6293↗
  13. GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery. First author DOI 10.1016/j.xcrm.2024.101557↗
  14. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  15. NFIC regulates ribosomal biology and ER stress in pancreatic acinar cells and restrains PDAC initiation. Last author DOI 10.1038/s41467-023-39291-x↗
  16. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Last author DOI 10.1136/gutjnl-2021-325803↗
  17. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Co-author DOI 10.1158/1055-9965.epi-23-0453↗
  18. A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2020-321397↗
  19. A faecal microbiota signature with high specificity for pancreatic cancer. Co-author DOI 10.1136/gutjnl-2021-324755↗
  20. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33464↗
  21. A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. Co-author DOI 10.1016/j.ajhg.2021.09.002↗
  22. Pancreatic cancer transcriptomes: molecular stratification in the adjuvant setting. Co-author DOI 10.1016/j.annonc.2020.11.012↗
  23. Publisher Correction: Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice Co-author DOI 10.1038/s41598-021-85032-9↗
  24. Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. Co-author DOI 10.1097/cej.0000000000000588↗
  25. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Co-author DOI 10.1136/gutjnl-2019-319990↗
  26. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Co-author DOI 10.1186/s13073-020-00816-4↗
  27. Cell Lineage Infidelity in PDAC Progression and Therapy Resistance. Co-author DOI 10.3389/fcell.2021.795251↗
  28. Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice. Co-author DOI 10.1038/s41598-020-74947-4↗
  29. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Co-author DOI 10.1158/0008-5472.can-20-0447↗
  30. Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. Co-author DOI 10.1158/1055-9965.epi-19-1027↗
  31. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer. Co-author DOI 10.15252/embj.2019102808↗
  32. Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. Co-author DOI 10.1002/ijc.31866↗
  33. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy155↗
  34. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Co-author DOI 10.1136/gutjnl-2017-314828↗
  35. Mutant Kras Dosage and Chromothripsis: The Right Ingredients for a Pancreatic Cancer Catastrophe. Co-author DOI 10.1016/j.trecan.2018.04.004↗
  36. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  37. Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. Co-author DOI 10.1093/ije/dyx269↗
  38. A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. Co-author DOI 10.1093/annonc/mdx167↗
  39. Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Co-author DOI 10.1136/gutjnl-2015-310442↗
  40. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Last author DOI 10.1136/gutjnl-2015-311256↗
  41. A genetic roadmap of pancreatic cancer: still evolving. Last author DOI 10.1136/gutjnl-2016-313317↗
  42. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.10.013↗
  43. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Co-author DOI 10.1038/nature19823↗
  44. Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors. Last author DOI 10.1158/1535-7163.mct-15-0214↗
  45. PanGen-Fam: Spanish registry of hereditary pancreatic cancer. Co-author DOI 10.1016/j.ejca.2015.07.004↗
  46. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Co-author DOI 10.1016/j.pan.2014.10.001↗
  47. A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2015/587250↗
  48. Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-14-2467↗
  49. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/ng.3052↗
  50. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1053/j.gastro.2014.06.041↗

Closest collaborators

The 25 strongest of 202 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Núria Malats · 25 shared papers, 2011–2026 · strength 2.41
  2. Alfredo Carrato · 15 shared papers, 2011–2025 · strength 1.12
  3. William Greenhalf · 13 shared papers, 2015–2025 · strength 1.05
  4. Irene Felipe‐Abrio · 4 shared papers, 2023–2025 · strength 0.94
  5. Eithne Costello · 12 shared papers, 2015–2024 · strength 0.87
  6. Jorg H. Kleeff · 10 shared papers, 2015–2025 · strength 0.81
  7. Tatjana Crnogorac‐Jurcevic · 10 shared papers, 2015–2025 · strength 0.80
  8. Thomas Mathias Gress · 10 shared papers, 2014–2025 · strength 0.79
  9. Matthias J. Löhr · 10 shared papers, 2015–2025 · strength 0.79
  10. Christoph W. Michalski · 8 shared papers, 2017–2026 · strength 0.77
  11. Luis Muñoz‐Bellvís · 9 shared papers, 2017–2025 · strength 0.76
  12. J. Enrique Domínguez‐Muñoz · 9 shared papers, 2017–2025 · strength 0.76
  13. Aldo Scarpa · 9 shared papers, 2016–2024 · strength 0.62
  14. Rita Teresa Lawlor · 7 shared papers, 2017–2025 · strength 0.62
  15. Paola Martinelli · 6 shared papers, 2011–2026 · strength 0.61
  16. Evangelina López de Maturana · 3 shared papers, 2024–2025 · strength 0.60
  17. Linda Sharp · 8 shared papers, 2017–2024 · strength 0.58
  18. Bo Kong · 8 shared papers, 2017–2024 · strength 0.58
  19. Dieter Saur · 3 shared papers, 2022–2026 · strength 0.57
  20. Iréne Esposito · 3 shared papers, 2020–2026 · strength 0.56
  21. Esther Molina‐Montes · 8 shared papers, 2017–2022 · strength 0.56
  22. Mónica P. de Andrés · 3 shared papers, 2018–2026 · strength 0.55
  23. Paulina Gómez-Rubio · 8 shared papers, 2017–2022 · strength 0.54
  24. Weimin Ye · 6 shared papers, 2018–2024 · strength 0.52
  25. Jens Thomas Siveke · 2 shared papers, 2021–2026 · strength 0.52

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.